Veröffentlichungen
Originalarbeiten, Bücher, Buchkapitel und Übersichtsartikel von Prof. Marcus Maurer
Verwendung: Beginnen Sie mit einer Übersicht über alle Publikationen. Verwenden Sie Tag-Links, um markierte Dokumente aufzulisten oder eine ganze Kategorie aufzulisten, z.B. Original Work (Originalarbeiten), Books (Bücher), Book Chapters (Buchkapitel), Reviews (Übersichtsartikel). Wenn Sie wissen, was Sie suchen, dann geben Sie diesen Begriff in das Suchfeld ein.
Up-dosing with bilastine results in improved effectiveness in cold contact urticaria
Filename | 165. Krause et al BUCUM Updosing Bilastine cold urticaria Allergy 2013 Original.pdf |
Filesize | 352,70 kB |
Version | o.165 |
Date added | Juni 5, 2020 |
Downloaded | 0 times |
Category | Original Work |
Tags | cold contact urticaria, cytokines, H1-antihistamine, histamine |
Authors | Krause, K., Spohr, A., Zuberbier, T., Church. M. K., and Maurer, M. |
Citation | Krause, K., Spohr, A., Zuberbier, T., Church. M. K., and Maurer, M.: Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy 2013: 68; 921-928. |
Corresponding authors | Church. M. K. |
DocNum | O.165 |
DocType | |
Edition; Page | 68; 921-928 |
IF | 5.99 |
Publisher | Allergy |
ReleaseDate | 2013 |
Background: Cold contact urticaria (CCU) is characterized by itchy wheal and flare responses due to the release of histamine and other pro-inflammatory media- tors after exposure to cold. The treatment of choice is nonsedating antihista- mines, dosages of which may be increased up to fourfold if standard doses are ineffective. Here, we assess the effects of a standard 20 mg dose and up-dosing to 40 and 80 mg of bilastine in reducing the symptoms of CCU and inflammatory mediator release following cold challenge.
Methods: Twenty patients with CCU were included in this randomized, crossover, double-blind, placebo-controlled 12-week study. They received placebo, 20, 40 or 80 mg of bilastine daily each for 7 days with 14-day washout periods. The pri- mary readout was change in critical temperature thresholds (CTT). Secondary readouts were changes in pruritus, levels of histamine IL-6, IL-8 and TNF-a col- lected by skin microdialysis and safety and tolerability of bilastine.
Results: Bilastine 20 mg was highly effective (P < 0.0001) in reducing CTT. Up-dosing to 80 mg significantly (P < 0.04) increased its effectiveness. At this dose, 19 of 20 (95%) patients responded to treatment, with 12 of 20 (60%) becoming symptom free. Only one patient was refractory to treatment. Microdialysis levels of histamine, IL-6 and IL-8 assessed 1–3 h after cold challenge were significantly (P < 0.05) decreased following up-dosing with 80 mg bilastine. Bilastine treat- ment was well tolerated without evidence of increased sedation with dose escala- tion.
Conclusions: Bilastine was effective in reducing the symptoms of patients with CCU. Increased efficacy of bilastine with fourfold up-dosing was without seda- tion and supports urticaria treatment guidelines.
(Last update: 12.2023)
Number of original publications in peer-reviewed journals: | 580 |
Number of reviews in peer-reviewed journals: | 210 |
Number of publications (original work and reviews) in peer-reviewed journals: | 790 |
Cumulative IF for original publications in peer-reviewed journals: | 4196.39 |
Cumulative IF for reviews in peer-reviewed journals: | 1409.32 |
Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 5605.71 |
Total number of citations: 36,836, h-index: 99 (Web of Science December 2023) | 36836 |
Download-Information
Um die angebotenen Veröffentlichungen herunterladen zu können, müssen Sie sich einloggen. Wenn Sie das Login nicht kennen, schreiben Sie mir bitte Ihre Anfrage.